CalciMedica
CALC
25 hedge funds and large institutions have $7.17M invested in CalciMedica in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 6 closing their positions.
612% more call options, than puts
Call options by funds: $178K | Put options by funds: $25K
7% less funds holding
Funds holding: 27 → 25 (-2)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
50% less capital invested
Capital invested by funds: $14.2M → $7.17M (-$7.03M)
Top Buyers
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$148K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$50.3K |
| 3 |
Two Sigma Investments
New York
|
-$33K |
| 4 |
BlackRock
New York
|
-$31.1K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$11.7K |
CALC Hedge Fund Activity: Q2 2022 in Review
25 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in CalciMedica (CALC) for Q2 2022, worth a combined $7.17M — down 50% from $14.2M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of CALC and 4 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 4 added.
The largest buyer was Renaissance Technologies, adding an estimated $16.3K. The largest seller was Morgan Stanley, cutting an estimated $148K.
- 25 institutional investors held CalciMedica (CALC) as of Q2 2022, down from 27 in Q1 2022.
- Funds reported $7.17M of CalciMedica stock for Q2 2022, down 50% quarter-over-quarter.
- 4 funds opened new CalciMedica positions in Q2 2022 and 6 closed out, a net change of -2 holders.
- The largest CalciMedica buyer in Q2 2022 was Renaissance Technologies, an estimated $16.3K added.
- The largest CalciMedica seller in Q2 2022 was Morgan Stanley, an estimated $148K sold.
Based on aggregated 13F filings for Q2 2022.